A1 Refereed original research article in a scientific journal

Striatal Dopamine Transporter and Rest Tremor in Parkinson Disease




AuthorsNiemi, Kalle J.; Jaakkola, Elina; Myller, Elina Maaria; Eklund, Mikael R. E.; Nuuttila, Simo; Mertsalmi, Tuomas; Murtomäki, Kirsi-Marja; Levo, Reeta; Noponen, Tommi; Ihalainen, Toni; Scheperjans, Filip; Joutsa, Juho; Kaasinen, Valtteri

Publication year2026

Journal: Neurology

Article numbere214811

Volume106

Issue7

ISSN0028-3878

eISSN1526-632X

DOIhttps://doi.org/10.1212/WNL.0000000000214811

Publication's open availability at the time of reportingOpen Access

Publication channel's open availability Partially Open Access publication channel

Web address https://doi.org/10.1212/wnl.0000000000214811

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/522855048

Self-archived copy's licenceCC BY NC ND

Self-archived copy's versionPublisher`s PDF


Abstract
Background and Objectives

The mechanisms underlying tremor generation in Parkinson disease (PD) remain unclear. Previously, we demonstrated a connection between rest tremor amplitude and higher dopamine transporter (DAT) binding in the ipsilateral striatum among the Parkinson Progression Markers Initiative cohort. Here, we investigated the association of parkinsonian motor symptoms with striatal DAT binding in a sizable and clinically representative sample of patients with parkinsonian signs to validate the previously observed ipsilateral relationship in PD.

Methods

This observational cross-sectional study included right-handed patients referred for [123I]FP-CIT SPECT because of clinically uncertain parkinsonism or tremor at Turku University Hospital and the Helsinki and Uusimaa Hospital District, Finland. Each patient underwent a comprehensive clinical evaluation and follow-up (median 3.0 years [interquartile range (IQR) 2.5]). Associations between striatal tracer binding and symptoms were investigated using voxel-wise linear models, adjusting for age, sex, motor symptom severity, and medication. The primary outcome measure was the association between rest tremor amplitude and striatal DAT binding.

Results

At the end of the follow-up period, of the 414 patients included (median age 68 years [IQR 14], 49.4% female), 148 were evaluated to have PD and 79 other forms of parkinsonism with striatal DAT deficit. In total, 187 patients had normal binding. Among the patients with PD, left and right rest tremor amplitudes were positively associated with ipsilateral striatal DAT binding (β = +0.12 [95% CI +0.05, +0.19] and +0.10 [+0.05, +0.15] specific binding ratio [SBR] per point; pFWE + Bonf. < 0.05, respectively). Left and right bradykinesia (β = −0.16 [−0.22, −0.09] and −0.18 [−0.25, −0.10] SBR per 5 points, pFWE + Bonf. < 0.05, respectively) and rigidity (β = −0.07 [−0.08, −0.04] and −0.08 [−0.11, −0.05] SBR per point, pFWE + Bonf. < 0.05, respectively) mainly showed a negative association with contralateral striatal DAT binding. No consistent associations were observed in non-PD groups.

Discussion

These findings confirm the positive association between rest tremor amplitude and ipsilateral striatal DAT binding in a clinical sample of PD patients. However, the non-PD groups were diagnostically heterogeneous, limiting conclusions about disease specificity.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
This study was funded by the Finnish Parkinson Foundation, the Finnish Cultural Foundation, the Turku University Foundation, TYKS Foundation, and Satakunta Wellbeing Services County. PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie Inc., AcureX Therapeutics, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's (ASAP), Avid Pharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol Myers Squibb, Calico Life Sciences LLC, Celgene Corporation, DaCapo Brainscience, Denali Therapeutics, the Edmond J. Safra Foundation, Eli Lilly and Company, GE Healthcare, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Pharmaceuticals, Lundbeck, Merck & Co. Inc., Meso Scale Diagnostics LLC, Pfizer Inc., Piramal Imaging, Prevail Therapeutics, F. Hoffmann‐La Roche Ltd. and its affiliated company Genentech Inc., Sanofi Genzyme, Servier, Takeda Pharmaceutical Company, Teva Neuroscience Inc., UCB, Vanqua Bio, Verily Life Sciences, Voyager Therapeutics Inc., and Yumanity Therapeutics Inc.


Last updated on 23/04/2026 02:25:19 PM